Pharmacopsychiatry最新文献_第10页

Metformin is Protective Against the Development of Mood Disorders. 二甲双胍可以预防情绪障碍的发展。

IF 4.3 3区医学

Pharmacopsychiatry Pub Date : 2023-01-01 DOI: 10.1055/a-1936-3580

Jacqueline Lake, Chiara C Bortolasci, Amanda L Stuart, Julie A Pasco, Srisaiyini Kidnapillai, Briana Spolding, Trang T T Truong, Bruna Panizzutti, Zoe S J Liu, Olivia M Dean, Tamsyn Crowley, Mark Richardson, Jee Hyun Kim, Michael Berk, Lana J Williams, Ken Walder

{"title":"Metformin is Protective Against the Development of Mood Disorders.","authors":"Jacqueline Lake, Chiara C Bortolasci, Amanda L Stuart, Julie A Pasco, Srisaiyini Kidnapillai, Briana Spolding, Trang T T Truong, Bruna Panizzutti, Zoe S J Liu, Olivia M Dean, Tamsyn Crowley, Mark Richardson, Jee Hyun Kim, Michael Berk, Lana J Williams, Ken Walder","doi":"10.1055/a-1936-3580","DOIUrl":"https://doi.org/10.1055/a-1936-3580","url":null,"abstract":"Introduction: Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale. The aim of this project was to identify drugs suitable for repurposing to treat mood disorders.Methods: This mixed-method study utilized gene expression signature technology and pharmacoepidemiology to investigate drugs that may be suitable for repurposing to treat mood disorders.Results: The transcriptional effects of a combination of drugs commonly used to treat mood disorders included regulation of the steroid and terpenoid backbone biosynthesis pathways, suggesting a mechanism involving cholesterol biosynthesis, and effects on the thyroid hormone signaling pathway. Connectivity Map analysis highlighted metformin, an FDA-approved treatment for type 2 diabetes, as a drug having global transcriptional effects similar to the mood disorder drug combination investigated. In a retrospective cohort study, we found evidence that metformin is protective against the onset of mood disorders.Discussion: These results provide proof-of-principle of combining gene expression signature technology with pharmacoepidemiology to identify potential novel drugs for treating mood disorders. Importantly, metformin may have utility in the treatment of mood disorders, warranting future randomized controlled trials to test its efficacy.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 1","pages":"25-31"},"PeriodicalIF":4.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10469482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis. 抗精神病药单一疗法治疗重度抑郁症:系统回顾和荟萃分析。

IF 4.3 3区医学

Pharmacopsychiatry Pub Date : 2023-01-01 DOI: 10.1055/a-1934-9856

Akira Nishi, Kyosuke Sawada, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi

{"title":"Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis.","authors":"Akira Nishi, Kyosuke Sawada, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi","doi":"10.1055/a-1934-9856","DOIUrl":"https://doi.org/10.1055/a-1934-9856","url":null,"abstract":"Although several randomized controlled trials (RCTs) have compared the effectiveness, efficacy, and safety of antipsychotic monotherapy (APM) versus placebo in patients with major depressive disorder (MDD), no meta-analysis has examined this topic. We conducted a systematic literature search using MEDLINE and Embase to identify relevant RCTs and performed a meta-analysis to compare the following outcomes between APM and placebo: response and remission rates, study discontinuation due to all causes, lack of efficacy, and adverse events, changes in total scores on depression severity scales, and individual adverse event rates. A total of 13 studies were identified, with 14 comparisons involving 3,197 participants that met the eligibility criteria. There were significant differences between APM and placebo in response and remission rates and changes in the primary depression severity scale in favor of APM, and study discontinuation due to adverse events and several individual adverse events in favor of placebo. No significant difference was observed in discontinuation due to all causes. APM could have antidepressant effects in the acute phase of MDD, although clinicians should be aware of an increased risk of some adverse events.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 1","pages":"5-17"},"PeriodicalIF":4.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10482603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Functional connectivity analysis of locus coeruleus in patients with major depressive episode 重度抑郁发作患者蓝斑的功能连通性分析

IF 4.3 3区医学

Pharmacopsychiatry Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1757657

Anastasia Gaspert, R. Schülke, Tabea Bätge, T. Folsche, N. Mahmoudi, Mike Wattjes, C. Sinke, Tillmann Krüger, S. Bleich, A. Neyazi, H. Frieling, H. Maier

引用次数: 0

Psychiatric syndromes associated with anti-neural autoantibodies differ in their affective psychopathology from those that are not 与抗神经自身抗体相关的精神综合征，其情感性精神病理与非相关的精神病理不同

IF 4.3 3区医学

Pharmacopsychiatry Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1757642

I. Grenzer, A. Juhl, D. Fitzner, J. Wiltfang, Niels Hansen

引用次数: 0

Neurological soft signs are increased in major depressive disorder irrespective of antidepressant treatment 无论是否进行抗抑郁治疗，严重抑郁症的神经系统软症状都会增加

IF 4.3 3区医学

Pharmacopsychiatry Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1757665

R. Schülke, K. Liepach, AnnaL Brömstrup, T. Folsche, M. Deest, S. Bleich, A. Neyazi, H. Frieling, H. Maier

引用次数: 0

Processing and recall of safety- and threat cues: The influence of oxytocin and the menstrual cycle 安全和威胁线索的处理和回忆：催产素和月经周期的影响